AIM：Gastro-esophageal reflux disease (GERD) is becoming increasingly common in Asia. Data on the efficacy of proton pump inhibitors in patients with non-erosive GERD (NERD)in Asia is lacking. This double-blind study ...AIM：Gastro-esophageal reflux disease (GERD) is becoming increasingly common in Asia. Data on the efficacy of proton pump inhibitors in patients with non-erosive GERD (NERD)in Asia is lacking. This double-blind study compared the efficacy and safety of rabeprazole with esomeprazole in relief of symptoms in patients with NERD.METHODS: One hundred and thirty-four patients with reflux symptoms of NERD and normal endoscopy were randomized to receive rabeprazole 10 mg or esomeprazole 20 mg once daily for 4 wk. Symptoms were recorded in a diary and changes in severity of symptoms noted.RESULTS: At 4 wk of treatment, rabeprazole 10 mg and esomeprazole 20 mg were comparable with regards to the primary endpoint of time to achieve 24-h symptomfree interval for heartburn 8.5 d vs9 d and regurgitation 6 d vs 7.5 d. Rabeprazole and esomeprazole were also similarly efficacious in term of patient's global evaluation with 96% of patients on rabeprazole and 87.9% of patients on esomeprazole, reporting that symptoms improved(P=NS). Satisfactory relief of day- and night-time symptoms was achieved in 98% of patients receiving rabeprazole and 81.4% of patients receiving esomeprazole. Adverse events were comparable in both groups (P = NS).CONCLUSION: Rabeprazole 10 mg has a similar efficacy and safety profile in Asians with NERD as esomeprazole 20 mg. Further study is necessary to investigate whether the small differences between the two drugs seen in this study are related to the improved pharmacodynamicpro perties of rabeprazole. Both drugs were well tolerated.展开更多
Objective： We assessed the safety and efficacy of two regimens for patients with gastrointestinal cancers： continuous-infusion （CI） schedules of 5-Fluorouracil （5-Fu） plus a platinum （cisplatin or oxaliplatin）...Objective： We assessed the safety and efficacy of two regimens for patients with gastrointestinal cancers： continuous-infusion （CI） schedules of 5-Fluorouracil （5-Fu） plus a platinum （cisplatin or oxaliplatin） with/or without paclitaxel （regimen A） versus Xeloda plus a platinum （cisplatin or oxaliplatin） with/or without paclitaxel for oral use （regimen B） in patients with gastrointestinal cancers. Methods： Between May 2003 and May 2005, 84 patients diagnosed in Jiangsu Cancer Hospital ＆ Research Institute with locally advanced esophageal, gastnc or colorectal cancer were registered. Regimen A and B consisted of either 5-Fu 0.375 CI days 1-14, every 28 days （n = 44）, or Xeloda 1000 mg twice daily, days 1-14, every 28 days （n = 40）. For both regimen A and B, IV cisplatin 25 mg/m^2 was administered on day 1, 2 and 3 （or Oxaliplatin 75mg/m^2 on day 1, 8 and 15） with or without paclitaxel 60-75 mg/m^2 on day1, 8 and 15. Results： Patients receiving regimen B experienced significantly less stomatitis （P 〈 0.05） and diarrhea （P 〈 0.05）, than those receiving regimen A. Prevalence of nausea/vomiting, alopecia, neutropenia, and hand-foot syndrome without significant difference between two regimens. No treatment related death occurred during study period. Regimen B demonstrates a similar, favorable safety profile in this study. Response rates and rates of clinical benefit for regimen A and B were 40.9%, 40.0% and 43.2%, 65.0% respectively. Conclusion： Based on its improved safety profile and improved rate of clinical benefit, Xeloda has the potential to replace CI 5-FU as an alternative treatment for patients with gastrointestinal cancers.展开更多
文摘AIM：Gastro-esophageal reflux disease (GERD) is becoming increasingly common in Asia. Data on the efficacy of proton pump inhibitors in patients with non-erosive GERD (NERD)in Asia is lacking. This double-blind study compared the efficacy and safety of rabeprazole with esomeprazole in relief of symptoms in patients with NERD.METHODS: One hundred and thirty-four patients with reflux symptoms of NERD and normal endoscopy were randomized to receive rabeprazole 10 mg or esomeprazole 20 mg once daily for 4 wk. Symptoms were recorded in a diary and changes in severity of symptoms noted.RESULTS: At 4 wk of treatment, rabeprazole 10 mg and esomeprazole 20 mg were comparable with regards to the primary endpoint of time to achieve 24-h symptomfree interval for heartburn 8.5 d vs9 d and regurgitation 6 d vs 7.5 d. Rabeprazole and esomeprazole were also similarly efficacious in term of patient's global evaluation with 96% of patients on rabeprazole and 87.9% of patients on esomeprazole, reporting that symptoms improved(P=NS). Satisfactory relief of day- and night-time symptoms was achieved in 98% of patients receiving rabeprazole and 81.4% of patients receiving esomeprazole. Adverse events were comparable in both groups (P = NS).CONCLUSION: Rabeprazole 10 mg has a similar efficacy and safety profile in Asians with NERD as esomeprazole 20 mg. Further study is necessary to investigate whether the small differences between the two drugs seen in this study are related to the improved pharmacodynamicpro perties of rabeprazole. Both drugs were well tolerated.
基金Supported by grants from the Jiangsu Provincial Personnel Department "the Great of Six Talented Man Peak" Project and the Jiangsu Cancer Hospital Emphasis Project (No. ZK200602).
文摘Objective： We assessed the safety and efficacy of two regimens for patients with gastrointestinal cancers： continuous-infusion （CI） schedules of 5-Fluorouracil （5-Fu） plus a platinum （cisplatin or oxaliplatin） with/or without paclitaxel （regimen A） versus Xeloda plus a platinum （cisplatin or oxaliplatin） with/or without paclitaxel for oral use （regimen B） in patients with gastrointestinal cancers. Methods： Between May 2003 and May 2005, 84 patients diagnosed in Jiangsu Cancer Hospital ＆ Research Institute with locally advanced esophageal, gastnc or colorectal cancer were registered. Regimen A and B consisted of either 5-Fu 0.375 CI days 1-14, every 28 days （n = 44）, or Xeloda 1000 mg twice daily, days 1-14, every 28 days （n = 40）. For both regimen A and B, IV cisplatin 25 mg/m^2 was administered on day 1, 2 and 3 （or Oxaliplatin 75mg/m^2 on day 1, 8 and 15） with or without paclitaxel 60-75 mg/m^2 on day1, 8 and 15. Results： Patients receiving regimen B experienced significantly less stomatitis （P 〈 0.05） and diarrhea （P 〈 0.05）, than those receiving regimen A. Prevalence of nausea/vomiting, alopecia, neutropenia, and hand-foot syndrome without significant difference between two regimens. No treatment related death occurred during study period. Regimen B demonstrates a similar, favorable safety profile in this study. Response rates and rates of clinical benefit for regimen A and B were 40.9%, 40.0% and 43.2%, 65.0% respectively. Conclusion： Based on its improved safety profile and improved rate of clinical benefit, Xeloda has the potential to replace CI 5-FU as an alternative treatment for patients with gastrointestinal cancers.
